Local control after palliative external beam radiotherapy for bone metastases in patients with favorable prognosis

被引：3

作者：

Makita, Kenji ^{[1
,2
,3
]}

Hamamoto, Yasushi ^{[2
]}

Kanzaki, Hiromitsu ^{[2
]}

Kataoka, Masaaki ^{[3
]}

Yamamoto, Shuhei ^{[3
]}

Nagasaki, Kei ^{[2
]}

Ishikawa, Hirofumi ^{[1
]}

Takata, Noriko ^{[1
]}

Tsuruoka, Shintaro ^{[1
]}

Uwatsu, Kotaro ^{[1
]}

Kido, Teruhito ^{[1
]}

机构：

[1] Ehime Univ, Dept Radiol, Grad Sch Med, Toon, Ehime 7910295, Japan

[2] Natl Hosp Org, Dept Radiat Oncol, Shikoku Canc Ctr, Matsuyama, Ehime 7910280, Japan

[3] Saiseikai Imabari Hosp, Dept Radiol, Imabari, Ehime 7991592, Japan

来源：

MOLECULAR AND CLINICAL ONCOLOGY | 2022年 / 17卷 / 05期

关键词：

bone metastasis; local control; fractionated moderate-dose palliative radiotherapy; individualized radiotherapy; RADIATION-THERAPY; PREOPERATIVE EVALUATION; SCORING SYSTEM; SPINE; RADIOSURGERY; FRACTIONATION; UPDATE;

D O I：

10.3892/mco.2022.2585

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Advancement in systemic therapy has increased the importance of local control (LC) of bone metastatic sites treated with radiotherapy in intermediate-term survivors (surviving >= 1 year). To establish individualized radiotherapy for bone metastases, factors affecting LC of bone metastases treated with traditional fractionated moderate dose palliative radiotherapy (FMRT) in intermediate-term survivors were evaluated. Between January 2010 and December 2019, 317 lesions in 240 patients treated with FMRT for bone metastases surviving for at least 1 year and followed-up with CT for at least 6 months were reviewed retrospectively. The median survival and radiographic follow-up times were 24 months (range, 12-123 months) and 20 months (range, 1-119 months), respectively. The median FMRT dose [biologically effective dose (BED)10] was 39.0 Gy (range, 28.0-71.7 Gy). Multivariate analysis revealed that age (>= 70 years), non-vertebral bone metastasis, bone metastasis from moderate and unfavorable primary tumor sites (esophageal, colorectal, hepatobiliary/pancreatic, kidney/ureter and sarcoma/melanoma cancers), and no administration of post-FMRT bone-modifying agents (BMAs) were unfavorable factors for LC of bone metastasis. The 2-year LC rates for FMRT doses (BED10) <= 39.0 Gy and >39.0 Gy were 90 and 87%, respectively. The 2-year LC rates of patients administered and not administered post-FMRT antineoplastic agents (ATs) were 91 and 78%, respectively. The sites of bone metastasis and primary tumors, and post-FMRT BMAs were factors associated with LC of bone metastasis in long-term survivors. However, a FMRT dose (BED10) >= 39.0 Gy and post-FMRT ATs were not significant factors.

引用

页数：7